1. Home
  2. OLMA vs SKY Comparison

OLMA vs SKY Comparison

Compare OLMA & SKY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OLMA
  • SKY
  • Stock Information
  • Founded
  • OLMA 2006
  • SKY 2010
  • Country
  • OLMA United States
  • SKY United States
  • Employees
  • OLMA N/A
  • SKY N/A
  • Industry
  • OLMA Biotechnology: Pharmaceutical Preparations
  • SKY Homebuilding
  • Sector
  • OLMA Health Care
  • SKY Consumer Discretionary
  • Exchange
  • OLMA Nasdaq
  • SKY Nasdaq
  • Market Cap
  • OLMA 465.4M
  • SKY N/A
  • IPO Year
  • OLMA 2020
  • SKY N/A
  • Fundamental
  • Price
  • OLMA $6.10
  • SKY $96.03
  • Analyst Decision
  • OLMA Strong Buy
  • SKY Hold
  • Analyst Count
  • OLMA 5
  • SKY 5
  • Target Price
  • OLMA $26.25
  • SKY $85.40
  • AVG Volume (30 Days)
  • OLMA 1.2M
  • SKY 1.3M
  • Earning Date
  • OLMA 11-12-2024
  • SKY 02-03-2025
  • Dividend Yield
  • OLMA N/A
  • SKY N/A
  • EPS Growth
  • OLMA N/A
  • SKY N/A
  • EPS
  • OLMA N/A
  • SKY 2.58
  • Revenue
  • OLMA N/A
  • SKY $2,340,474,000.00
  • Revenue This Year
  • OLMA N/A
  • SKY $20.55
  • Revenue Next Year
  • OLMA N/A
  • SKY $7.01
  • P/E Ratio
  • OLMA N/A
  • SKY $37.16
  • Revenue Growth
  • OLMA N/A
  • SKY 16.86
  • 52 Week Low
  • OLMA $5.56
  • SKY $64.82
  • 52 Week High
  • OLMA $16.78
  • SKY $116.49
  • Technical
  • Relative Strength Index (RSI)
  • OLMA 27.05
  • SKY 38.51
  • Support Level
  • OLMA $5.56
  • SKY $93.06
  • Resistance Level
  • OLMA $6.87
  • SKY $110.09
  • Average True Range (ATR)
  • OLMA 0.81
  • SKY 3.70
  • MACD
  • OLMA -0.28
  • SKY -1.64
  • Stochastic Oscillator
  • OLMA 10.12
  • SKY 12.68

About OLMA Olema Pharmaceuticals Inc.

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Share on Social Networks: